|
Overall Morningstar Rating™ |
| What is this? |
 |
 |
| As of 2009-10-31 |
 |
Out of Health Funds |
 |
| Rating derived from a weighted average of the fund's 3, 5, 10-year rating which are based on risk-adjusted performance. |
 |
|
 |
Morningstar® Style Box™ |
| What is this? |
 |
 |
|
Medium |
|
|
Growth |
|
|
|
 |
|
|
|
 |
| As of
2009-09-30 |
|
 |
| Day Change |
| $ -0.02 |
|
|
| NAV (2009-11-20) |
| $ 12.73 |
|
|
| YTD Return % (2009-11-20) |
| 24.60% |
|
|
| Total Assets ($ mil) |
| 124 |
|
| Growth of $10,000 |
 |
Fund: |
JHT Health Sciences Trust Ser NAV |
| (from
2005-04-29
to 2009-10-31) |
 |
Category: |
Health |
|
 |
Index: |
S&P 500 TR |
| Total Annualized Returns % |
1yr, 3yr and 5yr Returns as of 2009-11-20 |
| Inception date: 2005-04-29 |
10yr and Inception Returns as of 2009-10-31 |
|
YTD Returns as of 2009-11-20 |
|
|
YTD |
1 Year |
3 Year |
5 Year |
10 Year |
Since Inception |
| Fund |
24.60 |
52.37 |
1.30 |
--- |
--- |
5.92 |
| +/- Category |
14.55 |
43.62 |
3.92 |
--- |
--- |
--- |
| +/- S&P 500 TR |
1.08 |
3.57 |
7.20 |
--- |
--- |
--- |
 |
 |
| Standardized Annual Returns % more on standardized returns |
| Quarter-End (as of
2009-09-30) |
24.21 |
-0.23 |
2.73 |
--- |
--- |
7.36 |
| Month-End (as of 2009-10-31) |
17.55 |
14.68 |
-0.29 |
--- |
--- |
5.92 |
 |
 |
| After Tax Returns % (as of
2009-09-30
)
|
| On Distribution |
--- |
14.42 |
-1.87 |
--- |
--- |
--- |
| On Distribution & Sale of Shares |
--- |
9.80 |
-0.56 |
--- |
--- |
--- |
 |
 |
| Morningstar Rating |
--- |
--- |
 |
--- |
--- |
--- |
 |
| # of compared funds covered (3 yrs : out of 151 funds), (5 yrs : out of funds), (10 yrs : out of funds). Ratings are based on risk-adjusted performance. The maximum initial sales fee is
none,
the maximum deferred sales fee is
none,
and the maximum redemption sales fee is
none. |
 |
| The performance quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate thus an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted herein. |
|
 |
 |
 |
| Sector Breakdown % |
|
 |
Information |
2.49 |
 |
Software |
2.15 |
 |
Hardware |
0.34 |
 |
Media |
0.00 |
 |
Telecommunications |
0.00 |
 |
 |
 |
 |
Service |
96.28 |
 |
Healthcare |
87.50 |
 |
Consumer Services |
6.73 |
 |
Business Services |
0.37 |
 |
Financial Services |
1.69 |
 |
 |
 |
 |
Manufacturing |
1.23 |
 |
Consumer Goods |
0.00 |
 |
Industrial Materials |
1.23 |
 |
Energy |
0.00 |
 |
Utilities |
0.00 |
 |
|
 |
|
| |
|
|
| Asset Allocation |
|
 |
|
| % of Net Assets |
 |
Cash |
0.9 |
 |
Stocks |
98.2 |
 |
Bonds |
0.0 |
 |
Other |
0.9 |
 |
 |
|
Foreign Stocks |
14.8 |
|
(as a % of Assets) |
|
|
| Data through 2009-09-30 |
Data through 2009-09-30 |
 |
| Holding Status |
|
| Total Number of Stock Holdings |
146 |
|
Turnover % |
51 |
| Total Number of Bond Holdings |
0 |
|
30 Day SEC Yield % |
--- |
| % of Assets in Top 10 Holdings |
29.38 |
|
ending as of
2009-09-30 |
|
|
|
|
View Data Definitions |
| Top 10 Holdings |
Sector |
P/E |
YTD Return % |
% of Net Assets |
 |
 |
 |
 |
 |
 |
 |
Gilead Sciences, Inc. |
 |
24.33 |
-9.29 |
5.69 |
 |
Alexion Pharmaceuticals, Inc. |
 |
92.59 |
20.75 |
3.87 |
 |
Baxter International Inc. |
 |
16.95 |
2.84 |
3.29 |
 |
Medco Health Solutions, Inc. |
 |
19.69 |
47.01 |
2.77 |
 |
Roche Holding AG |
 |
31.75 |
6.86 |
2.57 |
|
 |
 |
Teva Pharmaceutical Industries, Ltd. ADR |
 |
54.64 |
24.98 |
2.48 |
 |
Express Scripts |
 |
17.73 |
54.77 |
2.42 |
 |
Henry Schein, Inc. |
 |
13.33 |
37.72 |
2.39 |
 |
Amgen, Inc. |
 |
14.81 |
-4.10 |
2.02 |
 |
Vertex Pharmaceuticals |
 |
--- |
26.86 |
1.88 |
|
 |
 |
Data through 2009-09-30 |
| YTD Return through 2009-11-20 |
|
| Fund Inception: 2005-04-29 |
|
Portfolio Manager (Start Date) |
|
|
|
 |
|
Kris H. Jenner (2001-04-30) |
|
|
|
Kris Jenner is a Vice President, Portfolio Manager, and Investment Analyst with T. Rowe Price. He joined the firm in June of 1997 and has five years of previous investment experience. He specializes in the coverage of the biotechnology and domestic pharmaceutical sectors of the health care industry. Kris earned a B.S. (Chemistry), summa cum laude from the University of Illinois, a D. Phil. from Oxford university/England, and a M.D. from the Johns Hopkins School of Medicine. |
|
|
|
|
Sales Charge % (taken from prospectus dated 2009-10-01) |
| Front: |
None |
| Deferred: |
None |
 |
| Expense Ratio % |
1.12 |
based on net assets
(taken from annual report dated 2008-12-31)
|
|
| Correspondence Information |
601 Congress Street
Boston,
MA
02210 USA |
|
|
|
| Telephone: |
| 800-344-1029 |
| 617-663-3000 |
|
|